August 15, 2019
Authored and Edited by Brandon T. Andersen; Samhitha Muralidhar Medatia; Elizabeth D. Ferrill
In Amgen Inc. v. Coherus Biosciences Inc., No. 2018-1993 (Fed. Cir. July 29, 2019), the Federal Circuit affirmed the district court’s dismissal of Amgen’s infringement claim under the doctrine of equivalents. The asserted patent claimed certain methods of purifying proteins involving the use of any of three particular combinations of salts. Coherus’s acknowledged purification method employed a combination of salts but not one of particular three claimed combinations.
The Federal Circuit held that prosecution history estoppel barred Amgen from succeeding on its infringement claim under the doctrine of equivalents because, during prosecution, Amgen “clearly and unmistakably surrendered” salt combinations other than the three particular combinations recited in the claims. The file history showed that, in response to an obviousness rejection, Amgen had argued that the cited reference failed to disclose the particular salt combinations recited in Amgen’s claims. The argument was not the only one Amgen raised, nor was it included in the remarks that ultimately led to allowance. Nevertheless, the Court reasoned that each argument in support of patentability can create a separate estoppel, including assertions that were not actually required to secure allowance.
Copyright © 2019 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Conference
Best Practices in Intellectual Property– A Decade of Dedication to IP Excellence
April 8-9, 2024
Tel Aviv
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.